| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.096 | 0.02 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.095 | 0.02 |
| mRNA | MP470 | GDSC1000 | pan-cancer | AAC | 0.082 | 0.02 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.079 | 0.02 |
| mRNA | SCH-529074 | CTRPv2 | pan-cancer | AAC | 0.098 | 0.02 |
| mRNA | paclitaxel | GDSC1000 | pan-cancer | AAC | -0.12 | 0.02 |
| mRNA | importazole | CTRPv2 | pan-cancer | AAC | 0.098 | 0.02 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.14 | 0.02 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | 0.078 | 0.02 |
| mRNA | navitoclax:birinapant (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.092 | 0.02 |